ScreenerHero

MNPR Monopar Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · monopartx.com
83.78USD+5.29%Mkt Cap: 562.35M $P/E: —

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational onc…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap562.35M USD
Enterprise Value399.99M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.72M USD
Revenue/Share—
Last Price83.78 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-41.53
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B4.08
EPS (TTM)-2.23
EPS (Forward)-1.92
52W Range
50.0745% of range124.42
52W High124.42 USD
52W Low50.07 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-9.95%
ROA-9.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.20M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.08%
Net Debt-134.09M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio33.56
Quick Ratio33.44
Book Value/Sh19.50 USD
Cash/Share20.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateAug 13, 2024
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)129.92 USD
Upside (mean)+55.1%
Target Range119.00 USD – 145.00 USD
119.00+55.1% to mean145.00
# Analysts12
Ownership
Shares Out.6.71M
Float4.47M
Insiders23.47%
Institutions94.82%
Short Interest
Short Ratio5.4d
Short % Float18.41%
Short % Out.12.58%
Shares Short844.23K
Short (prev mo.)887.19K
Technical
SMA 50106.46 (-21.3%)
SMA 20076.50 (+9.5%)
Beta1.51
S&P 52W Chg16.45%
Avg Vol (30d)165.33K
Avg Vol (10d)160.76K
Technical Indicators
RSI (14)35.4
MACD-8.0395
MACD Signal-7.1914
MACD Hist.-0.8481
BB Upper118.88 USD
BB Middle92.64 USD
BB Lower66.41 USD
BB Width56.63%
ATR (14)5.275 USD
Vol Ratio (20d)0.65x